1980 Participants Needed

Healthy Heart Program for High Blood Pressure and High Cholesterol

KC
LN
Overseen ByLaurie Norton, MA, MBE
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Pennsylvania
Must be taking: Statins
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

To leverage access to patients across the primary care network, EPIC tools for identifying eligible patients, and the Way to Health platform to launch and enroll a program that will be evaluated in a clinical trial that is focused on changing patient behavior and powered to detect differences in improving blood pressure and cholesterol over 6 months for Penn Medicine patients in West/Southwest Philadelphia and Lancaster.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it seems to focus on patients not using certain cholesterol medications like PCSK9 inhibitors or high-intensity statins. It's best to discuss your specific medications with the trial team.

What data supports the effectiveness of the treatment Penn Med Healthy Heart Program for high blood pressure and high cholesterol?

Research shows that community-based programs and educational interventions can help improve blood pressure control, as seen in studies like the Minnesota Heart Health Program and the HEROIC study, which both demonstrated improvements in blood pressure management through education and community efforts.12345

How is the Penn Med Healthy Heart Program treatment different from other treatments for high blood pressure and high cholesterol?

The Penn Med Healthy Heart Program is unique because it focuses on a comprehensive, coordinated intervention that involves both healthcare providers and the general public, aiming to improve access to quality care for high blood pressure and high cholesterol.36789

Research Team

KV

Kevin Volpp, MD PhD

Principal Investigator

University of Pennsylvania

Eligibility Criteria

This trial is for Penn Medicine patients in West/Southwest Philadelphia and Lancaster with high blood pressure or cholesterol. Eligible participants may have heart disease, a risk score of ≥10%, diabetes, an A1c level ≥6.5, or LDL levels ≥190 within the past five years. They must not be on certain cholesterol medications and have had high systolic blood pressure readings recently.

Inclusion Criteria

Last 2 Blood Pressure readings with Systolic Blood Pressure >=140 from any outpatient encounter in the last 12 months
On the Penn Medicine Primary Care Service Line registry
I have heart disease, diabetes, high cholesterol, or am at high risk for heart disease.
See 1 more

Exclusion Criteria

Documented statin allergy/ or intolerance in the EMR
Pregnancy
I need a translator to communicate in English.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants engage in the Penn Medicine Healthy Heart program, which includes receiving a blood pressure monitor and completing 4 HDPP modules over 6 months

6 months

Follow-up

Participants are monitored for changes in blood pressure and cholesterol levels after the intervention

4 weeks

Treatment Details

Interventions

  • Penn Med Healthy Heart Program
Trial OverviewThe trial tests the Penn Med Healthy Heart Program aimed at changing patient behavior to improve blood pressure and cholesterol over six months using EPIC tools for patient identification and the Way to Health platform for program enrollment.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Penn Med Healthy Heart ProgramExperimental Treatment1 Intervention
The Intervention group will receive the blood pressure monitor and move through the 4 HDPP modules of the intervention.
Group II: Usual CareActive Control1 Intervention
This group will not receive the intervention and will continue with usual care.

Penn Med Healthy Heart Program is already approved in United States for the following indications:

🇺🇸
Approved in United States as Penn Medicine Healthy Heart for:
  • Cardiovascular disease risk reduction
  • Hypertension management
  • Cholesterol management

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Pennsylvania

Lead Sponsor

Trials
2,118
Recruited
45,270,000+

Findings from Research

The National High Blood Pressure Education Program (NHBPEP) has significantly increased public awareness, treatment, and control of hypertension, leading to a remarkable decline in heart disease and stroke mortality rates by 70% and 80%, respectively, over four decades.
This decline in mortality rates is observed across different demographics, including both sexes and racial groups, particularly benefiting those in the southeastern U.S., despite rising obesity and diabetes rates.
The treatment of hypertension: a remarkable success story.Moser, M., Roccella, EJ.[2023]
The Minnesota Heart Health Program is a comprehensive ten-year initiative aimed at preventing coronary heart disease through community-wide efforts, including systematic hypertension screening and educational programs.
By implementing multiple strategies across different sites and conducting annual surveys, the program aims to gather evidence on the effectiveness of these prevention methods in reducing heart disease risk factors.
[Prevention and treatment of hypertension at the population level: the Minnesota Heart Health Program].Murray, D., Luepker, R., Grimm, R., et al.[2017]
The HEROIC study involved 226 physicians and assessed the impact of an educational program on blood pressure control in nearly 2500 hypertensive patients, resulting in a small but significant reduction of -1.1 mm Hg in systolic blood pressure after one year.
While there was a slight increase in the proportion of patients reaching their blood pressure targets (from 13.6% to 15.6%), the overall improvement was not enough to prevent the risk of developing heart failure, indicating that more intensive interventions are necessary.
Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HEROIC study.De Rivas, B., Barrios, V., Redón, J., et al.[2021]

References

The treatment of hypertension: a remarkable success story. [2023]
2.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[Prevention and treatment of hypertension at the population level: the Minnesota Heart Health Program]. [2017]
Effectiveness of an Interventional Program to Improve Blood Pressure Control in Hypertensive Patients at High Risk for Developing Heart Failure: HEROIC study. [2021]
Evaluation of the hypertension disease management program in Korea. [2019]
Community Targeting of Uncontrolled Hypertension: Results of a Hypertension Screening and Education Intervention in Community Churches Serving Predominantly Racial/Ethnic Minority Populations. [2022]
Healthy Heart Africa-Kenya: A 12-Month Prospective Evaluation of Program Impact on Health Care Providers' Knowledge and Treatment of Hypertension. [2020]
Feeling supported and abandoned: mixed messages from attendance at a rural community cardiac rehabilitation program in Australia. [2015]
Lessons learned from the Healthy Heart Community Prevention Project in reaching the African American population. [2022]
Prevention and control of hypertension by nutritional-hygienic means. Long-term experience of the Chicago Coronary Prevention Evaluation Program. [2016]